Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
31 March, 2026
TROG Secondary Data Analysis Grant awarded to project to better understand prostate cancer therapy outcomes
LATEST NEWS: 31 March 2026 TROG’s inaugural Secondary Data
26 March, 2026
TROG welcomes new Board members and President-Elect
LATEST NEWS: 26 March 2026 We are delighted to